​

Editas Medicine (EDIT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

EDIT Stock Forecast

Editas Medicine (EDIT) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 136.22% increase from the last price of $2.54.

$1 $3 $5 $7 $9 $11 High: $6 Avg: $6 Low: $6 Last Closed Price: $2.54

EDIT Stock Rating

Editas Medicine stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (56.00%), 9 Hold (36.00%), 2 Sell (8.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 2 9 14 0 Strong Sell Sell Hold Buy Strong Buy

EDIT Price Target Upside V Benchmarks

TypeNameUpside
StockEditas Medicine136.22%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$6.00$6.00$6.00
Last Closing Price$2.54$2.54$2.54
Upside/Downside136.22%136.22%136.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-66-214
Feb, 26-66-214
Jan, 26-67-215
Dec, 25-67-215
Nov, 25138-214
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Robert W. Baird$6.00$2.32158.62%136.22%
Nov 05, 2024Gena WangBarclays$5.00$3.1260.26%96.85%
Oct 23, 2024Yanan ZhuWells Fargo$9.00$3.29173.56%254.33%
Oct 22, 2024Joel BeattyRobert W. Baird$10.00$3.29203.95%293.70%
Aug 08, 2024Joon LeeTruist Financial$12.00$4.24183.02%372.44%
Aug 08, 2024Greg HarrisonBank of America Securities$15.00$4.21256.29%490.55%
May 30, 2024Liisa BaykoEvercore ISI$7.00$5.1037.25%175.59%
May 09, 2024Matthew HarrisonMorgan Stanley$7.00$5.0438.89%175.59%
Sep 28, 2023Dae Gon HaStifel Nicolaus$17.00$6.92145.66%569.29%
Dec 13, 2022Citigroup$11.00$9.9610.44%333.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 09, 2026Cowen & Co.BuyBuyhold
Aug 15, 2025H.C. WainwrightBuyBuyhold
Apr 28, 2025H.C. WainwrightBuyinitialise
Nov 06, 2024Evercore ISIOutperformupgrade
Nov 05, 2024OppenheimerPerformPerformhold
Nov 05, 2024BarclaysMixedMixedhold
Nov 04, 2024RBC CapitalSector PerformSector Performhold
Oct 23, 2024Wells FargoSector PerformSector Performhold
Oct 23, 2024Wells FargoOverweightOverweighthold
Aug 08, 2024Bank of America SecuritiesBuyupgrade

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.85$-3.21$-2.02$-2.88$-1.80---
Avg Forecast$-3.01$-3.05$-2.40$-2.70$-1.39$-1.23$-1.37$-1.27
High Forecast$0.48$0.64$-1.60$-2.32$-0.89$-0.62$-0.97$-0.33
Low Forecast$-7.80$-11.34$-2.69$-3.04$-2.41$-1.83$-1.75$-4.54
Surprise %-5.32%5.25%-15.83%6.67%29.50%---

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$25.54M$19.71M$78.12M$32.31M----
Avg Forecast$17.41M$16.59M$21.99M$34.36M$8.72M$5.43M$13.20M$30.22M
High Forecast$38.70M$51.31M$50.85M$53.91M$26.01M$16.20M$39.37M$90.13M
Low Forecast$1.88M$1.15M$12.42M$3.72M$3.74M$2.33M$5.67M$12.97M
Surprise %46.75%18.84%255.28%-5.95%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-192.50M$-220.43M$-153.22M$-237.09M$-160.06M---
Avg Forecast$-203.25M$-226.29M$-153.22M$-210.57M$-144.63M$-93.01M$-103.61M$-96.36M
High Forecast$-162.60M$-181.04M$-122.58M$-176.38M$-67.63M$-46.86M$-73.91M$-24.86M
Low Forecast$-243.89M$-271.55M$-183.86M$-230.88M$-183.12M$-139.15M$-133.32M$-344.75M
Surprise %-5.29%-2.59%-12.59%10.67%---

EDIT Forecast FAQ

Is Editas Medicine stock a buy?

Editas Medicine stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 9 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Editas Medicine is a favorable investment for most analysts.

What is Editas Medicine's price target?

Editas Medicine's price target, set by 25 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 136.22% change from the previous closing price of $2.54.

How does Editas Medicine stock forecast compare to its benchmarks?

Editas Medicine's stock forecast shows a 136.22% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Editas Medicine over the past three months?

  • March 2026: 0% Strong Buy, 42.86% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.
  • February 2026: 0% Strong Buy, 42.86% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.
  • January 2026: 0% Strong Buy, 40.00% Buy, 46.67% Hold, 0% Sell, 13.33% Strong Sell.

What is Editas Medicine’s EPS forecast?

Editas Medicine's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.23, marking a -31.67% decrease from the reported $-1.8 in 2025. Estimates for the following years are $-1.37 in 2027, and $-1.27 in 2028.

What is Editas Medicine’s revenue forecast?

Editas Medicine's average annual revenue forecast for its fiscal year ending in December 2026 is $5.43M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $13.2M, and $30.22M for 2028.

What is Editas Medicine’s net income forecast?

Editas Medicine's net income forecast for the fiscal year ending in December 2026 stands at $-93.007M, representing a -41.89% decrease from the reported $-160M in 2025. Projections indicate $-104M in 2027, and $-96.362M in 2028.